Comparative Pharmacology
Head-to-head clinical analysis: RITODRINE HYDROCHLORIDE versus RITODRINE HYDROCHLORIDE IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RITODRINE HYDROCHLORIDE versus RITODRINE HYDROCHLORIDE IN DEXTROSE 5 IN PLASTIC CONTAINER.
RITODRINE HYDROCHLORIDE vs RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; stimulates beta-2 receptors in uterine smooth muscle, causing relaxation and inhibiting uterine contractions.
Ritodrine is a beta-2 adrenergic receptor agonist that stimulates adenylate cyclase, increasing cyclic AMP levels, leading to relaxation of uterine smooth muscle. It also has some beta-1 activity.
Intravenous: Initial 0.1 mg/min, increased by 0.05 mg/min every 10-15 min until contractions cease or intolerance; max 0.35 mg/min. Oral: 10-20 mg every 2-4 hours, start 30 min before IV discontinuation.
Intravenous infusion: initial rate 0.05 mg/min (50 mcg/min), increase by 0.05 mg/min every 10 minutes until effective or maternal heart rate >130 bpm; maximum rate 0.35 mg/min (350 mcg/min). Maintenance: continue at lowest effective rate for 12-48 hours after contractions cease.
None Documented
None Documented
Terminal elimination half-life: 1.7-2.6 hours (mean 2.0 h) in pregnant women; prolonged in renal impairment.
Terminal elimination half-life: 15-26 hours (mean 20 hours) in adults; prolonged in renal impairment.
Renal: 70-90% as unchanged drug and metabolites (mainly glucuronide and sulfate conjugates); biliary/fecal: minor (<10%).
Renal: >90% as unchanged drug and metabolites; biliary/fecal: minimal (<5%).
Category C
Category C
Tocolytic Agent
Tocolytic Agent